Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis

Publikation

Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis

Wissenschaftlicher Artikel/Review - 13.09.2010

Jörger Markus, Matter-Walstra K, Früh Martin, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M

Zitation

Jörger M, Matter-Walstra K, Früh M, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M. Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Ann Oncol 2010; 22:567-74.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Ann Oncol 2010; 22

Veröffentlichungsdatum

13.09.2010

eISSN (Online)

1569-8041

Seiten

567-74

Kurzbeschreibung/Zielsetzung

Adding cetuximab to standard chemotherapy results in a moderate increase of overall survival in patients with advanced non-small-cell lung cancer (NSCLC), but the cost-effectiveness is unknown. Materials and methods: A Markov model was constructed based on the results of the First-Line ErbituX in lung cancer randomized trial, adding cetuximab to cisplatin-vinorelbine first-line chemotherapy in patients with advanced NSCLC. The primary outcome was the incremental cost-effectiveness ratio (ICER) of adding cetuximab, expressed as cost per quality-adjusted life year (QALY) gained, and relative to a willingness-to-pay threshold of EUR60 000/QALY. The impact of cetuximab intermittent dosing schedules on the ICER was also evaluated.